m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03084
 [1]
m6A modification HDAC4 HDAC4 ALKBH5 Demethylation : m6A sites Direct Inhibition Histone modification HIF1A HDAC4 Downstream Gene
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
m6A Target Histone deacetylase 4 (HDAC4)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Histone deacetylase 4 (HDAC4) ERASER View Details
Regulated Target Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A) View Details
Crosstalk Relationship m6A  →  Histone modification Inhibition
Crosstalk Mechanism m6A modification impacts directly histone modification through modulating the expression level of histone-associated enzymes
Crosstalk Summary m6A methylation recognized by m6A reader-YTHDF2 enhanced the stability of Histone deacetylase 4 (HDAC4), and then promoted glycolytic metabolism and migration of PC cells. m6A methylation regulates hypoxia-induced pancreatic cancer glycolytic metabolism through ALKBH5-HDAC4-Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A) positive feedback loop
Responsed Disease Pancreatic cancer ICD-11: 2C10
 Disease Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Histone deacetylase 4 (HDAC4) 104 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PMID29671355-Compound-52 Patented [2]
MOA Inhibitor
Activity IC50 = 55 nM
External Link
CID: 117603070
TTD: D02YLT
 Compound Name PMID29671355-Compound-72a Patented [2]
MOA Inhibitor
Activity IC50 = 3 nM
External Link
TTD: D03KOH
 Compound Name PMID29671355-Compound-47c Patented [2]
MOA Inhibitor
Activity IC50 = 40 nM
External Link
CID: 72948227
TTD: D07KQB
 Compound Name PMID29671355-Compound-70 Patented [2]
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 122669618
TTD: D08CYC
 Compound Name PMID29671355-Compound-71b Patented [2]
MOA Inhibitor
Activity IC50 = 8 nM
External Link
TTD: D0BV4M
 Compound Name PMID29671355-Compound-72b Patented [2]
MOA Inhibitor
Activity IC50 = 21 nM
External Link
TTD: D0E7TU
 Compound Name PMID29671355-Compound-47a Patented [2]
MOA Inhibitor
Activity IC50 = 10 nM
External Link
CID: 72722126
TTD: D0L1NO
 Compound Name PMID29671355-Compound-50 Patented [2]
MOA Inhibitor
Activity IC50 = 12 nM
External Link
TTD: D0M7GG
 Compound Name PMID29671355-Compound-47b Patented [2]
MOA Inhibitor
Activity IC50 = 20 nM
External Link
CID: 72950863
TTD: D0NG9V
 Compound Name PMID29671355-Compound-71a Patented [2]
MOA Inhibitor
Activity IC50 = 3 nM
External Link
TTD: D0O1LX
 Compound Name PMID29671355-Compound-47d Patented [2]
MOA Inhibitor
Activity IC50 = 40 nM
External Link
CID: 72948224
TTD: D0SP7T
 Compound Name PMID29671355-Compound-12 Patented [2]
MOA Inhibitor
Activity IC50 = 120 nM
External Link
CID: 78425879
TTD: D0UE9B
 Compound Name PMID29671355-Compound-68b Patented [2]
MOA Inhibitor
Activity IC50 = 2.74 nM
External Link
TTD: D0GD6R
 Compound Name PMID29671355-Compound-45a Patented [2]
MOA Inhibitor
Activity IC50 = 49 nM
External Link
CID: 86302836
TTD: D0YN2T
 Compound Name PMID29671355-Compound-61 Patented [2]
MOA Inhibitor
Activity IC50 > 1000000 nM
External Link
TTD: D0JB4S
 Compound Name PMID29671355-Compound-23 Patented [2]
MOA Inhibitor
Activity IC50 = 3820 nM
External Link
CID: 118884610
TTD: D00HXJ
 Compound Name PMID29671355-Compound-56 Patented [2]
MOA Inhibitor
Activity IC50 = 9220 nM
External Link
CID: 56965342
TTD: D0CH8Q
 Compound Name PMID29671355-Compound-67 Patented [2]
MOA Inhibitor
Activity IC50 = 2840 nM
External Link
CID: 60201048
TTD: D0M0RE
 Compound Name PMID29671355-Compound-31 Patented [2]
MOA Inhibitor
Activity IC50 = 1970 nM
External Link
CID: 90479372
TTD: D0DI9S
DrugBank: DB14979
 Compound Name PMID29671355-Compound-21 Patented [2]
MOA Inhibitor
Activity IC50 = 16400 nM
External Link
CID: 86295624
TTD: D0LP1K
 Compound Name PMID29671355-Compound-62 Patented [2]
MOA Inhibitor
Activity IC50 = 100 to 500 nM
External Link
TTD: D07WAT
 Compound Name PMID29671355-Compound-43 Patented [2]
MOA Inhibitor
Activity IC50 > 100000 nM
External Link
CID: 118515590
TTD: D0BP8I
 Compound Name PMID29671355-Compound-25 Patented [2]
MOA Inhibitor
Activity IC50 = 3310 nM
External Link
CID: 126569528
TTD: D0RA0D
 Compound Name N-hydroxy-9,10-dihydroanthracene-9-carboxamide Investigative [3]
Synonyms
CHEMBL575482; SCHEMBL4541357
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2320 nM
External Link
CID: 45482666
TTD: D03BQS
 Compound Name N-hydroxy-2,2-diphenylacetamide Investigative [3]
Synonyms
Diphenylacetohydroxamic acid; 4099-51-8; N-Hydroxy diphenylacetamide; CHEMBL396097; NSC44620; benzeneacetamide, n-hydroxy-; A-phenyl-; N-Hydroxydiphenylacetamide; BENZENEACETAMIDE,N-HYDROXY-A-PHENYL-; AC1Q5QC3; SCHEMBL2839032; CTK8I6435; DTXSID10286297; AC1L6390; ZINC4522248; NSC-44620; BDBM50207561; MFCD16314231; AKOS022308585; Diphenylacetohydroxamic acid, &gt
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 250 nM
External Link
CID: 239512
TTD: D03QOD
 Compound Name N-hydroxy-9H-xanthene-9-carboxamide Investigative [3]
Synonyms
CHEMBL583490; 9H-Xanthene-9-carboxamide,N-hydroxy-; SCHEMBL2843958; BDBM50300446
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 250 nM
External Link
CID: 44626296
TTD: D06IMY
 Compound Name 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide Investigative [3]
Synonyms
CHEMBL574594; SCHEMBL4536216
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 700 nM
External Link
CID: 45482630
TTD: D0A4HF
 Compound Name AZUMAMIDE E Investigative [4]
Synonyms
CHEMBL402363
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2280 nM
External Link
CID: 16095101
TTD: D0E9DD
 Compound Name 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide Investigative [3]
Synonyms
CHEMBL573190; SCHEMBL2841871
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1100 nM
External Link
CID: 45482672
TTD: D0FN5D
 Compound Name N-hydroxy-2,2-diphenylpropanamide Investigative [3]
Synonyms
CHEMBL585365; SCHEMBL2844474
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4500 nM
External Link
CID: 45482660
TTD: D0I4RK
 Compound Name AZUMAMIDE B Investigative [4]
Synonyms
CHEMBL402727
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3660 nM
External Link
CID: 16095112
TTD: D0M1ZI
 Compound Name 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide Investigative [3]
Synonyms
CHEMBL572805; SCHEMBL2848402
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 960 nM
External Link
CID: 45482643
TTD: D0PK9V
 Compound Name AZUMAMIDE C Investigative [4]
Synonyms
CHEMBL257972
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3160 nM
External Link
CID: 16095114
TTD: D0Q9PO
 Compound Name LARGAZOLE Investigative [5]
Synonyms
CHEMBL1173445; (+)-Largazole; SCHEMBL71330; ZINC56861395
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3000 nM
External Link
CID: 24757913
TTD: D0Z8PX
 Compound Name Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) Investigative [6]
Synonyms
CHEMBL393260
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 25 nM
External Link
CID: 44437872
TTD: D00XTC
 Compound Name 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide Investigative [7]
Synonyms
CHEMBL419758; NCH-31; JMC505425 Compound 7; BDBM19131; 7-mercapto-N-(4-phenyl-2-thiazolyl)heptanamide; N-(4-phenyl-1,3-thiazol-2-yl)-7-sulfanylheptanamide
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 32 nM
External Link
CID: 11427204
TTD: D02HVH
 Compound Name Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) Investigative [6]
Synonyms
CHEMBL390991
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.4 nM
External Link
CID: 44437870
TTD: D02NAF
 Compound Name Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) Investigative [6]
Synonyms
CHEMBL394261
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1.6 nM
External Link
CID: 44437869
TTD: D02NVY
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) Investigative [6]
Synonyms
CHEMBL391384
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.7 nM
External Link
CID: 44437878
TTD: D03PRG
 Compound Name Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) Investigative [6]
Synonyms
CHEMBL393261
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 70 nM
External Link
CID: 44437873
TTD: D04CDZ
 Compound Name santacruzamate A Investigative [8]
Synonyms
CAY10683
    Click to Show/Hide
MOA Inhibitor
Activity IC50 > 1000 nM
External Link
CID: 72946782
TTD: D09RKA
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) Investigative [6]
Synonyms
CHEMBL241555
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1.6 nM
External Link
CID: 44437879
TTD: D0E8UH
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) Investigative [6]
Synonyms
CHEMBL428737
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 56 nM
External Link
CID: 44437876
TTD: D0G1EX
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) Investigative [6]
Synonyms
CHEMBL238587
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4.2 nM
External Link
CID: 44437875
TTD: D0N5RV
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) Investigative [6]
Synonyms
CHEMBL238596; BDBM50222727
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5.2 nM
External Link
CID: 44437883
TTD: D0R3XO
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) Investigative [6]
Synonyms
CHEMBL393961
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 4 nM
External Link
CID: 44437880
TTD: D0U0EZ
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) Investigative [6]
Synonyms
CHEMBL391383
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3.2 nM
External Link
CID: 44437877
TTD: D0X4QC
 Compound Name Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) Investigative [6]
Synonyms
CHEMBL393464
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2.2 nM
External Link
CID: 44437874
TTD: D0Z6HR
 Compound Name Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) Investigative [6]
Synonyms
CHEMBL238829; BDBM50222732
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1.8 nM
External Link
CID: 44437868
TTD: D0Z6MI
 Compound Name TMP269 Investigative [9]
Synonyms
TMFO1; compound 1 [PMID: 23524983]; TMP-269; TMP 269
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 90.5 nM
External Link
CID: 53344908
TTD: D0R7JA
 Compound Name 8-Oxo-8-phenyl-octanoic acid hydroxyamide Investigative [10]
Synonyms
CHEMBL95959; SCHEMBL3383197; N-hydroxy-8-oxo-8-phenyloctanamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11075845
TTD: D0S0WK
 Compound Name ST-3050 Investigative [11]
Synonyms
CHEMBL472631; SCHEMBL3445133; SCHEMBL3445139; BDBM50278222
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 16100 nM
External Link
CID: 44591988
TTD: D01YBR
 Compound Name Octanedioic acid bis-hydroxyamide Investigative [12]
Synonyms
Suberohydroxamic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5173
TTD: D07YZZ
 Compound Name 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Investigative [10]
Synonyms
9,9,9-Trifluoro-8-Oxo-N-Phenylnonanamide; CHEMBL113537; 2gh6; SCHEMBL2702892; KRCXZGYVOZSCSF-UHFFFAOYSA-N; BDBM50121062; DB07553
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 5.1 nM
External Link
CID: 9882812
TTD: D00KFF
DrugBank: DB07553
 Compound Name 7-Mercapto-heptanoic acid phenylamide Investigative [13]
Synonyms
Thiol-SAHA (t-SAHA); CHEMBL325676; SCHEMBL14821761; BDBM152692
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11379392
TTD: D00SEE
 Compound Name 6-benzenesulfinylhexanoic acid hydroxamide Investigative [14]
Synonyms
6-(benzenesulfinyl)hexanoic acid hydroxyamide; 875737-03-4
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11694528
TTD: D00ZSD
 Compound Name N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Investigative [15]
Synonyms
CHEMBL193959
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44401339
TTD: D01MFV
 Compound Name 7-Mercapto-heptanoic acid biphenyl-4-ylamide Investigative [13]
Synonyms
CHEMBL112311
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11220728
TTD: D01XWZ
 Compound Name N-Hydroxy-4-phenylacetylamino-benzamide Investigative [16]
Synonyms
CHEMBL356824; 656261-23-3; SCHEMBL675578; CTK1J6158; DTXSID40458440; ZINC13533297; AKOS030583151; Benzeneacetamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11196500
TTD: D01XXN
 Compound Name 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Investigative [13]
Synonyms
CHEMBL344920; 651767-99-6; SCHEMBL3736839; CTK1J8444; DTXSID50432973; HWYLREOMBVUGJQ-UHFFFAOYSA-N; BDBM50222416; ZINC13587789; AKOS030603042; N-Phenyl-6-(bromoacetylamino)hexanamide; Hexanamide, 6-[(bromoacetyl)amino]-N-phenyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9927379
TTD: D02MQM
 Compound Name N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Investigative [17]
Synonyms
CHEMBL143674; SCHEMBL673760
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11323577
TTD: D02UTC
 Compound Name 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [18]
Synonyms
CHEMBL126355; BDBM50222394
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350626
TTD: D02WZK
 Compound Name Octanedioic acid hydroxyamide pyridin-4-ylamide Investigative [19]
Synonyms
SCHEMBL8082656; CHEMBL165162; ZINC13472304
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10967421
TTD: D04GGW
 Compound Name N-(6-Mercapto-hexyl)-benzamide Investigative [13]
Synonyms
CHEMBL112364; BDBM50223650
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11447748
TTD: D04HSS
 Compound Name 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative [19]
Synonyms
CHEMBL167455
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11086699
TTD: D04NSP
 Compound Name N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Investigative [16]
Synonyms
SCHEMBL675474
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11231829
TTD: D04ZDI
 Compound Name 6-benzenesulfonylhexanoic acid hydroxamide Investigative [14]
Synonyms
CHEMBL203207
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11572583
TTD: D05AHZ
 Compound Name 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Investigative [10]
Synonyms
SCHEMBL7373122; CHEMBL116578
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342872
TTD: D05FEJ
 Compound Name Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Investigative [13]
Synonyms
CHEMBL111806; SCHEMBL14812153
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11254470
TTD: D05GVY
 Compound Name 4-Butyrylamino-N-hydroxy-benzamide Investigative [17]
Synonyms
CHEMBL142254; 656261-22-2; Benzamide, N-hydroxy-4-[(1-oxobutyl)amino]-; SCHEMBL675234; CTK1J6159; DTXSID90461262
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11287488
TTD: D05LLX
 Compound Name 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [18]
Synonyms
CHEMBL127328
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350703
TTD: D05VFP
 Compound Name 7-Mercapto-heptanoic acid biphenyl-3-ylamide Investigative [13]
Synonyms
CHEMBL320323
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11449823
TTD: D05XAN
 Compound Name 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Investigative [20]
MOA Inhibitor
External Link
CID: 3082127
TTD: D06IQB
 Compound Name N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Investigative [16]
Synonyms
SCHEMBL676079
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11347053
TTD: D06VBN
 Compound Name 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Investigative [13]
Synonyms
CHEMBL324126
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11277483
TTD: D06XNP
 Compound Name 7-Mercapto-heptanoic acid pyridin-3-ylamide Investigative [13]
Synonyms
CHEMBL332246; Heptanamide, 7-mercapto-N-3-pyridinyl-; BDBM50223653
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11345433
TTD: D07FJU
 Compound Name 6-Phenoxy-hexane-1-thiol Investigative [13]
Synonyms
CHEMBL109796; 6-phenoxyhexane-1-thiol; 1-Hexanethiol, 6-phenoxy-; SCHEMBL5679745; MolPort-020-180-823; BDBM50223652; AKOS018584222; MCULE-9521857089
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11298778
TTD: D09YBN
 Compound Name 4-Benzoylamino-N-hydroxy-benzamide Investigative [16]
Synonyms
SCHEMBL673678; CHEMBL191227
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11817702
TTD: D09ZNU
 Compound Name 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Investigative [10]
Synonyms
CHEMBL143734; NSC718168; AC1L8L82; SCHEMBL13039735; ZINC5579677; BDBM50082664; NSC-718168; NCI60_040737; 6-(4-Chlorobenzoylamino)hexanehydroxamic acid
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 403373
TTD: D0A5LS
 Compound Name 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Investigative [18]
Synonyms
CHEMBL112148; SCHEMBL7364383; BDBM50218532
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44341053
TTD: D0AX7B
 Compound Name 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Investigative [18]
Synonyms
CHEMBL127351; SCHEMBL7365180; HWZHDGRMABBYOV-UHFFFAOYSA-N; BDBM50222367; 7-((1,1'-biphenyl)-3-yloxy)-1-(1 ,3-oxazol-2-yl)-1-heptanone
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350718
TTD: D0B2ZJ
 Compound Name 6-Mercapto-hexanoic acid phenylamide Investigative [13]
Synonyms
CHEMBL109654; Hexanamide, 6-mercapto-N-phenyl-; SCHEMBL14254925; BDBM50027600
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11436024
TTD: D0B3ZM
 Compound Name Cyclostellettamine derivative Investigative [21]
Synonyms
CHEMBL88332
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 23327627
TTD: D0C0VP
 Compound Name N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Investigative [10]
Synonyms
CHEMBL139999; SCHEMBL1232700; BDBM50082661; ZINC13472309
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9943996
TTD: D0C2KD
 Compound Name 5-Mercapto-pentanoic acid phenylamide Investigative [13]
Synonyms
N-Phenyl-5-mercaptovaleramide; CHEMBL114344; Pentanamide, 5-mercapto-N-phenyl-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11608171
TTD: D0D2KE
 Compound Name Octanedioic acid hydroxyamide pyridin-2-ylamide Investigative [19]
Synonyms
SCHEMBL8090513; CHEMBL164872; ZINC13472303
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11747496
TTD: D0E8KR
 Compound Name N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Investigative [15]
Synonyms
CHEMBL193979
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44401305
TTD: D0F0KS
 Compound Name 2-(methylsulfonylthio)ethyl 2-propylpentanoate Investigative [20]
Synonyms
CHEMBL271677; SCHEMBL4156413
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 24759251
TTD: D0H1FZ
 Compound Name (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Investigative [18]
Synonyms
CHEMBL126465; SCHEMBL7368197; SCHEMBL7368201
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44350655
TTD: D0KE3I
 Compound Name N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Investigative [16]
Synonyms
SCHEMBL676080
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11312563
TTD: D0QO0L
 Compound Name N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Investigative [16]
Synonyms
N-hydroxy-4-(3-phenylpropanamido)benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0R4BS
 Compound Name N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Investigative [16]
Synonyms
SCHEMBL7311087
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11472431
TTD: D0R5VG
 Compound Name 8-Oxo-8-phenyl-octanoic acid Investigative [19]
Synonyms
8-Oxo-8-phenyloctanoic acid; 7-Benzoylheptanoic acid; 24314-23-6; Benzeneoctanoic acid, h-oxo-; 7-BENZOYL HEPTANOIC ACID; AC1L6TSB; SCHEMBL3381106; 8-keto-8-phenyl-caprylic acid; CHEMBL162423; 8-Oxo-8-phenyloctanoic acid #; CTK4F3363; DTXSID40305602; UMCSRRHQLAVYRS-UHFFFAOYSA-N; ZINC2168376; 7009f; NSC171230; AKOS016022495; NSC-171230; MCULE-7202530747; ACM24314236; ST50825837
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 298878
TTD: D0RU1X
 Compound Name N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Investigative [16]
Synonyms
CHEMBL143336; 656261-24-4; SCHEMBL674421; CTK1J6157; DTXSID30433908; ZINC13533300; AKOS030583673; n-hydroxy-4-(4-phenylbutyryl-amino)benzamide; Benzenebutanamide, N-[4-[(hydroxyamino)carbonyl]phenyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9994848
TTD: D0S7WQ
 Compound Name 6-phenylsulfanylhexanoic acid hydroxamide Investigative [14]
Synonyms
Hexanamide, N-hydroxy-6-(phenylthio)-; CHEMBL203028; SCHEMBL7317658
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11637291
TTD: D0S9JF
 Compound Name ST-2987 Investigative [11]
Synonyms
CHEMBL471042; SCHEMBL3444989; SCHEMBL3444984; BDBM50278220
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2040 nM
External Link
CID: 44138032
TTD: D0T0SK
 Compound Name 7-Mercapto-heptanoic acid quinolin-3-ylamide Investigative [13]
Synonyms
CHEMBL112234
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10379373
TTD: D0T4IY
 Compound Name 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Investigative [22]
Synonyms
CHEMBL84288
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11528707
TTD: D0V2ZO
 Compound Name 8-Mercapto-octanoic acid phenylamide Investigative [13]
Synonyms
8-mercapto-N-phenyloctanamide; CHEMBL326433; ZINC13609343
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11149404
TTD: D0XZ9Q
 Compound Name N-(6-Hydroxycarbamoyl-hexyl)-benzamide Investigative [19]
Synonyms
CHEMBL57107; 174664-71-2; SCHEMBL573254; CTK0A7470; DTXSID00433435; BDBM50220823; ZINC13490043; 7-(Benzoylamino)heptanehydroxamic acid; AKOS030580013; Benzamide, N-[7-(hydroxyamino)-7-oxoheptyl]-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 9965141
TTD: D0YY9M
 Compound Name 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Investigative [10]
Synonyms
CHEMBL326529; SCHEMBL7365237; BDBM50217957
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44342825
TTD: D0Z3BM
 Compound Name 7-Mercapto-heptanoic acid benzothiazol-2-ylamide Investigative [13]
Synonyms
CHEMBL178779
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 11346934
TTD: D0Z5KX
 Compound Name N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Investigative [17]
Synonyms
CHEMBL143102
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 44361923
TTD: D0Z7YS
 Compound Name PSAMMAPLIN A Investigative [10]
Synonyms
110659-91-1; Bisprasin; NSC614495; AC1O46WI; SCHEMBL364511; ZINC150352860; NSC-614495; B723735K022; J-002461; Benzenepropanamide, N,N'-(dithiodi-2,1-ethanediyl)bis(3-bromo-4-hydroxy-alpha-(hydroxyimino)-
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 6400741
TTD: D0N0TS
Hypoxia-inducible factor 1-alpha (HIF-1-Alpha/HIF1A) 21 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name PT2385 Phase 2 [23]
Synonyms
ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 91754484
TTD: D0C9PZ
 Compound Name ISIS 298697 Investigative [24]
External Link
TTD: D00JHE
 Compound Name ISIS 298744 Investigative [24]
External Link
TTD: D01DDQ
 Compound Name ISIS 298746 Investigative [24]
External Link
TTD: D01ZCK
 Compound Name ISIS 298745 Investigative [24]
External Link
TTD: D07GVC
 Compound Name ISIS 298743 Investigative [24]
External Link
TTD: D09DCJ
 Compound Name ISIS 298702 Investigative [24]
External Link
TTD: D0B5LQ
 Compound Name ISIS 298700 Investigative [24]
External Link
TTD: D0C2IG
 Compound Name ISIS 175510 Investigative [24]
External Link
TTD: D0G9BP
 Compound Name ISIS 298699 Investigative [24]
External Link
TTD: D0L5ME
 Compound Name ISIS 298712 Investigative [24]
External Link
TTD: D0L9KW
 Compound Name ISIS 298711 Investigative [24]
External Link
TTD: D0SN5O
 Compound Name ISIS 298701 Investigative [24]
External Link
TTD: D0X8GB
 Compound Name (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol Investigative [25]
Synonyms
Lificiguat; yc-1; 170632-47-0; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole; YC 1; UNII-515CC1WPTE; Lificiguat(YC-1); 154453-18-6; [5-(1-benzyl-1h-indazol-3-yl)-2-furyl]methanol; 515CC1WPTE; CHEMBL333985; OQQVFCKUDYMWGV-UHFFFAOYSA-N; C19H16N2O2; 3-(5'-Hydroxymethyl-2'-furyl)-1-benzyl indazole; 1-Benzyl-3-(5-hydroxymethyl-2-furyl)indazole; [5-(1-benzyl-1H-indazol-3-yl)furan-2-yl]methanol; 5-[1-(Phenylmethyl)-1H-indazol-3-yl]-2-furanmethanol
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 5712
TTD: D00REK
 Compound Name HIF-1alpha Phase 4 [26]
Synonyms
Unii-NA856793UT; 192705-79-6; PD-166866; PD166866; PD 166866; CHEMBL299763; NA856793UT; 1-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butylurea; 1-(2-Amino-6-(3,5-dimethoxyphenyl)-pyrido(2,3-d)pyrimidin-7-yl)-3-tert-butyl urea; Urea,N-[2-amino-6-(3,5-dimethoxyphenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)-; 1-[2-Amino-6-(3,5-dimethoxyphenyl)-pyrido[2,3-d]pyrimidin-7-yl]-3-tert-butyl urea; 6-arylpyrido[2,3-d]pyrimidine deriv 25; AC1NS3U5; SCHEMBL1248489; BDBM3443; CTK4E1060
    Click to Show/Hide
External Link
CID: 5328127
TTD: D0B0AX
 Compound Name IT-101 Phase 3 [26]
External Link
TTD: D06PEW
 Compound Name 2-Methoxyestradiol Phase 2 [26]
Synonyms
ESM; Panzem; PulmoLAR; Panzem NCD; M 6383; (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol; (17beta)-2-methoxyestra-1(10),2,4-triene-3,17-diol; (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER; 1,3,5(10)-Estratriene-2,3,17-triol 2-methyl ether; 2,3,17beta-Trihydroxy-1,3,5(10)-estratriene 2-methyl ether; 2-Hydroxyestradiol 2-methyl ether; 2-Hydroxyestradol 2-methyl ether; 2-ME2, 2-Methoxyestradiol; 2-Methoxyestra-1,3,5(10)-triene-3,17beta-diol; 2-Methoxyestradiol-17beta; 3,17beta-Dihydroxy-2-methoxy-1,3,5(10)-estratriene
    Click to Show/Hide
External Link
CID: 66414
TTD: D06NYA
DrugBank: DB02342
 Compound Name PX-478 Phase 1 [26]
Synonyms
685898-44-6; PX-478 2HCl; UNII-T23U22X160; PX478; PX 478; Melphalan N-Oxide Impurity HCl; T23U22X160; 4-[Bis(2-chloroethyl)oxidoamino]-L-phenylalanine; PX-478 dihydrochloride; SCHEMBL18548830; C13H18Cl2N2O3.2ClH; DTXSID00218688; MolPort-035-789-733; 2675AH; s7612; 2-Amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide; AKOS030231369; CS-5164; HY-10231; KB-80169; Z-3209; L-Phenylalanine, 4-(bis(2-chloroethyl)oxidoamino)-, dihydrochloride; (S)-4-(2-amino-2-carboxyethyl)-N,N-bis(2-chloroethyl)aniline oxide di
    Click to Show/Hide
External Link
CID: 11234794
TTD: D06ZVO
DrugBank: DB06082
 Compound Name EZN-2968 Phase 1 [26]
External Link
TTD: D0NF5J
 Compound Name ENMD-1198 Phase 1 [26]
Synonyms
EM-5171; EM-883; EM-900; Hypoxia inducible factor 1 inhibitors, EntreMed; HIF-1 inhibitors, EntreMed; HIF-1 inhibitors (cancer), EntreMed; 2-ME2 analogs (oral, cancer), EntreMed; 2-methoxyestradiol analogs (oral, cancer), EntreMed
    Click to Show/Hide
External Link
CID: 11483754
TTD: D0Y5QD
DrugBank: DB05959
 Compound Name Pyrrolidine carboxamide derivative 1 Patented [26]
Synonyms
PMID26882240-Compound-22
    Click to Show/Hide
External Link
CID: 56684144
TTD: D0Q2SE
2C10: Pancreatic cancer 182 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Atezolizumab Approved [23]
External Link
TTD: D0YM2K
 Compound Name Trimethadione Approved [27]
Synonyms
Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]
    Click to Show/Hide
External Link
CID: 5576
TTD: D0U4VT
DrugBank: DB00347
 Compound Name Motixafortide Approved [23]
External Link
CID: 91865076
TTD: D0T6CN
DrugBank: DB14939
 Compound Name Uridine triacetate Approved [28]
Synonyms
PN401
    Click to Show/Hide
External Link
CID: 20058
TTD: D0OL7F
DrugBank: DB09144
 Compound Name Bentiromide Approved [29]
Synonyms
Bentiromide sodium; 41748-47-4; N-Benzoyl-L-tyrosyl-4-aminobenzoic acid sodium salt; NCGC00164607-01; EINECS 255-530-7; DSSTox_CID_26476; DSSTox_RID_81647; DSSTox_GSID_46476; DTXSID6046476; CHEMBL3188891; Tox21_112229; AKOS024373587; ACM41748474; Sodium (S)-4-((2-(benzoylamino)-3-(4-hydroxyphenyl)-1-oxopropyl)amino)benzoate; CAS-41748-47-4; FT-0771579; ST51012404; N-Benzoyl-L-tyrosine p-amidobenzoic acid sodium salt; sodium (S)-4-(2-benzamido-3-(4-hydroxyphenyl)propanamido)benzoate; N-Benzoyl-L-tyrosine p-amidobenzoic acid so
    Click to Show/Hide
External Link
CID: 6957673
TTD: D0L0SW
DrugBank: DB00522
 Compound Name Olaparib Approved [23]
Synonyms
AZD 2281; AZD2281; AZD-2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
    Click to Show/Hide
External Link
CID: 23725625
TTD: D0J9HW
DrugBank: DB09074
 Compound Name Streptozocin Approved [30]
Synonyms
Estreptozocina; STREPTOZOTOCIN; STRZ; Streptozocine; Streptozocinium; Streptozocinum; Streptozosin; Zanosar; Alkylating agent; Binds to DNA; Streptozocinium [Latin]; Streptozocine [INN-French]; Streptozocinum [INN-Latin]; Zanosar (TN); Streptozocin (USAN/INN); Streptozocin, Zanosar, STZ,Streptozotocin;N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine; N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff; N-D-Glucosyl-(2)-N'-nitrosomethylurea; D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)-(9CI); 1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea; 2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose; 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose; 2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose; 2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
    Click to Show/Hide
External Link
CID: 29327
TTD: D0I8RR
DrugBank: DB00428
 Compound Name Plazomicin Phase 3 [31]
Synonyms
ACHN-490; UNII-LYO9XZ250J; 1154757-24-0; LYO9XZ250J; Plazomicin [USAN:INN]; Plazomicin (USAN); ZINC68150640; DB12615; D10151; D-Streptamine,
    Click to Show/Hide
External Link
CID: 42613186
TTD: D0E6BB
DrugBank: DB12615
 Compound Name Taxol Approved [23]
Synonyms
C47H51NO14; weekly paclitaxel; Micellar Paclitaxel; Paclitaxel [USAN:INN:BAN]; SCHEMBL15000506; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
    Click to Show/Hide
External Link
CID: 36314
TTD: D0C4RB
DrugBank: DB01229
 Compound Name Ibrutinib Phase 3 [23]
Synonyms
PCI-32765; Ibrutinib (BTK inhibitor)
    Click to Show/Hide
External Link
CID: 24821094
TTD: D09KTS
DrugBank: DB09053
 Compound Name Erlotinib Approved [32]
Synonyms
Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
    Click to Show/Hide
External Link
CID: 176870
TTD: D07POC
DrugBank: DB00530
 Compound Name Ruxolitinib Approved [33]
Synonyms
Ruxolitinib (JAK inhibitor)
    Click to Show/Hide
External Link
CID: 25126798
TTD: D04LKS
DrugBank: DB08877
 Compound Name Nivolumab Approved [23]
External Link
TTD: D00GOV
 Compound Name Coenzyme Q10 Phase 2 [23]
Synonyms
CoQ10; Coenzyme Q10 (oral formulation); CoQ10 platform technology, Ryan (Receptagen); Coenzyme Q10 (oral formulation), Receptagen
    Click to Show/Hide
External Link
CID: 5281915
TTD: D01ZUA
DrugBank: DB09270
 Compound Name Aglatimagene besadenovec Phase 1/2 [23]
External Link
TTD: DE8H1W
 Compound Name Zolbetuximab Phase 3 [34]
Synonyms
IMAB362
    Click to Show/Hide
External Link
TTD: D4HQ1F
 Compound Name AC-1204 Phase 3 [35]
Synonyms
isoindoline hydrochloride; 32372-82-0; 2,3-Dihydroisoindole hydrochloride; 2,3-dihydro-1H-isoindole hydrochloride; 2,3-Dihydro-1H-isoindole HCl; Isoindoline HCl salt; 1H-Isoindole, 2,3-dihydro-, hydrochloride; Isoindoline hydrochloride, 97%; Isoindolinehydrochloride; Isoindoline, HCl; ISOINDOLINE HCL; AC1Q38WR; dihydroisoindole hydrochloride; KSC491I3F; AMBZ0192; SCHEMBL4702076; CTK3J1432; DTXSID50487241; MolPort-003-986-749; NOVIRODZMIZUPA-UHFFFAOYSA-N; BH168; CS-D1516; ACT08858; ACN-S003258; KS-000001RA
    Click to Show/Hide
External Link
CID: 12311031
TTD: D0Y1RN
 Compound Name Radiosensitizer gene therapy Phase 3 [36]
Synonyms
Radiosensitizer gene therapy (prostate cancer)
    Click to Show/Hide
External Link
TTD: D0X4NF
 Compound Name Glufosfomide Phase 3 [37]
External Link
TTD: D0W7PQ
 Compound Name Yttrium (90Y) clivatuzumab tetraxetan Phase 3 [38]
Synonyms
PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
    Click to Show/Hide
External Link
TTD: D0V2KR
 Compound Name Y-90 Clivatuzumab Phase 3 [39]
External Link
TTD: D0T8AI
 Compound Name Civacir Phase 3 [40]
External Link
TTD: D0P9UP
 Compound Name GV1001 Phase 3 [41]
External Link
TTD: D0N0QC
 Compound Name Masitinib Phase 3 [23]
Synonyms
790299-79-5; AB1010; Masatinib; Masitinib (AB1010); Masivet; AB-1010; AB 1010; UNII-M59NC4E26P; Masitinib [INN]; M59NC4E26P; 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]benzamide; CHEMBL1908391; CHEBI:63450; Masitinib (INN); N-(4-Methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide; Q-201339; C28H30N6OS; N-(4-methyl-3-(4-(pyridin-3-yl)thiazol-2-ylamino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
    Click to Show/Hide
External Link
CID: 10074640
TTD: D0MW0N
DrugBank: DB11526
 Compound Name Glufosfamide Phase 3 [23]
Synonyms
Glucosylifostamide mustard; D 19575; D-19575; Glc-IPM; Glucosyl-ifosfamide mustard; Beta-D-Glucopyranose 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate; Beta-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate); (2S,3R,4S,5S,6R)-2-bis(2-chloroethylamino)phosphoryloxy-6-(hydroxymethyl)oxane-3,4,5-triol
    Click to Show/Hide
External Link
CID: 123628
TTD: D0L9IA
DrugBank: DB06177
 Compound Name Sapacitabine Phase 3 [23]
Synonyms
CYC682
    Click to Show/Hide
External Link
CID: 153970
TTD: D0D4RF
DrugBank: DB06365
 Compound Name Pelareorep Phase 2 [42]
External Link
TTD: D0BF8Y
 Compound Name Pamrevlumab Phase 3 [43]
External Link
TTD: D09TJJ
 Compound Name GRASPA Phase 1 [44]
Synonyms
L-asparaginase (erythrocyte-encapsulated, acute lymphoblastic leukemia/solid tumor), ERYtech
    Click to Show/Hide
External Link
TTD: D09JKS
 Compound Name Pancreas algenpantucel-L Phase 3 [45]
Synonyms
HyperAcute (TN)
    Click to Show/Hide
External Link
TTD: D08PBQ
 Compound Name CPI-613 Phase 3 [46]
Synonyms
95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
    Click to Show/Hide
External Link
CID: 24770514
TTD: D07NVI
DrugBank: DB12109
 Compound Name Zarnestra Phase 3 [47]
Synonyms
JAN; Tipifarnib; Tipifarnib [USAN]; R 115777; R115777; R-11577; R-115777; Tipifarnib (USAN/INN); Zarnestra, IND 58359, R115777, Tipifarnib; (R)-6-(Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone; (R)-R115777; 2 (1H))-Quinolinone,6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-, 2(1H)-quinolinone; 6-[(R)-amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2(1H)-one; 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one; 6-[(S)-AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL]-4-(3-CHLOROPHENYL)-1-METHYLQUINOLIN-2(1H)-ONE
    Click to Show/Hide
External Link
CID: 159324
TTD: D07NPS
DrugBank: DB04960
 Compound Name MM-398 Phase 3 [48]
External Link
CID: 91809656
TTD: D07HOH
 Compound Name Marimastat Phase 3 [49]
Synonyms
Marimastat [USAN]; BB 2516; BB-2516; Marimastat (USAN/INN); (2R,3S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoxy)propyl)carboyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-3-(((1S)-2,2-Dimethyl-1-(methylcarbamoyl)propyl)carbamoyl)-2-hydroxy-5-methylhexanohydroxamic acid; (2S,3R)-N(4)-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-N(1),2-dihydroxy-3-(2-methylpropyl)butanediamide
    Click to Show/Hide
External Link
CID: 119031
TTD: D05VZE
DrugBank: DB00786
 Compound Name AM0010 Phase 3 [50]
External Link
TTD: D03MYX
 Compound Name ANX-510 Phase 3 [51]
External Link
CID: 135400185
TTD: D01YKI
 Compound Name Napabucasin Phase 3 [23]
Synonyms
83280-65-3; UNII-Z1HHM49K7O; 2-acetylnaphtho[2,3-b]furan-4,9-dione; Z1HHM49K7O; 2-Acetylnaphtho(2,3-b)furan-4,9-dione; 2-Acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione; Napabucasin [USAN:INN]; Napabucasin (BBI608); 2-Acetylfuranonaphthoquinone; CHEMBL64130; Napabucasin (JAN/USAN/INN); SCHEMBL1883845; Napabucasin - BBI 608/ FNQ; 2-Acetylfuro-1,4-naphthoquinone; DPHUWDIXHNQOSY-UHFFFAOYSA-N; MolPort-039-101-321; EX-A1314; ZINC13306865; s7977; AKOS027470201; DB12155; CS-1747; ACN-053294; HY-13919
    Click to Show/Hide
External Link
CID: 10331844
TTD: D01IGZ
DrugBank: DB12155
 Compound Name Algenpantucel-L Phase 3 [52]
Synonyms
HyperAcute pancreas (TN)
    Click to Show/Hide
External Link
TTD: D00HSK
 Compound Name OT-101 Phase 2/3 [23]
External Link
TTD: DO5H6K
 Compound Name RP101 Phase 2/3 [53]
Synonyms
SCHEMBL15589316; CHEMBL3703295; BDBM149820; US8975415,
    Click to Show/Hide
External Link
CID: 446727
TTD: D0Z9LP
DrugBank: DB03312
 Compound Name NLG8189 Phase 2/3 [23]
Synonyms
1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
    Click to Show/Hide
External Link
CID: 405012
TTD: D0B5HS
DrugBank: DB12827
 Compound Name LY2157299 Phase 2/3 [23]
Synonyms
Galunisertib; 700874-72-2; LY 2157299; LY-2157299; UNII-3OKH1W5LZE; 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 3OKH1W5LZE; Galunisertib (LY2157299); AK-79916; 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide; 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide; 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
    Click to Show/Hide
External Link
CID: 10090485
TTD: D06TFI
DrugBank: DB11911
 Compound Name SM-88 Phase 2/3 [54]
External Link
CID: 3125
TTD: D03ZDX
 Compound Name SiG12D-LODER Phase 2 [23]
External Link
TTD: DNH67V
 Compound Name BNT141 Phase 2 [55]
External Link
TTD: DFZ19J
 Compound Name BNT321 Phase 2 [56]
Synonyms
MVT-5873
    Click to Show/Hide
External Link
TTD: D7AOL8
 Compound Name BPM 31510 Phase 2 [57]
External Link
TTD: D4MZR2
 Compound Name GC4711 Phase 2 [58]
Synonyms
UNII-FW5T90VM32; FW5T90VM32; GC-4419 dipropionate; Bis-propionato(gc4419); Avasopasem manganese dipropionate; GC-4711; 2248030-85-3; Manganese(II), bis-propionato((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-11,7-nitrilo-7H-dibenzo(b,H)(1,4,7,10)tetraaza-cycloheptadecine-kn5,kn13,kn18,kn21,kn22)-,
    Click to Show/Hide
External Link
CID: 131634674
TTD: D3P8JK
 Compound Name CYTO-401 Phase 2 [59]
External Link
TTD: D2Q5XO
 Compound Name Zenocutuzumab Phase 2 [60]
External Link
TTD: D1J4CI
 Compound Name Cabiralizumab Phase 2 [23]
External Link
TTD: D0YO4B
 Compound Name VS-6063 Phase 2 [23]
Synonyms
Defactinib hydrochloride; 1073160-26-5; Defactinib (hydrochloride); UNII-L2S469LM49; Defactinib hydrochloride [USAN]; L2S469LM49; Defactinib hydrochloride (USAN); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsulfonyl)amino]-2-pyrazinyl]methyl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-, hydrochloride; Defactinib HCl; Benzamide, N-methyl-4-((4-(((3-(methyl(methylsulfonyl)amino)-2-pyrazinyl)methyl)amino)-5-(trifluoromethyl)-2-pyrimidinyl)amino)-, hydrochloride (1:1); Benzamide, N-methyl-4-[[4-[[[3-[methyl(methylsu
    Click to Show/Hide
External Link
CID: 25117126
TTD: D0Y1UO
DrugBank: DB12282
 Compound Name MENK Phase 2 [37]
External Link
TTD: D0VG7I
 Compound Name CO-101 Phase 2 [61]
Synonyms
methyl 2-(dimethylcarbamoyl)benzoate; 26593-43-1; Phthalamic acid, N,N-dimethyl-, methyl ester; CO 101; BRN 2504723; N,N-Dimethylphthalamic acid methyl ester; N,N-Dimethylphthalamic acid, methyl ester; AC1Q5ZAU; 2-09-00-00601 (Beilstein Handbook Reference); AC1L4V19; CTK4F8203; DTXSID50181156; 2-methoxycarbonyl-N,N-dimethylbenzamide; LS-109082; Benzoic acid,2-[(dimethylamino)carbonyl]-, methyl ester
    Click to Show/Hide
External Link
CID: 9828310
TTD: D0V0CJ
DrugBank: DB12564
 Compound Name MENK Phase 2 [23]
Synonyms
IRT-101
    Click to Show/Hide
External Link
TTD: D0TN1J
 Compound Name TL-118 Phase 2 [62]
Synonyms
Hamsa 1; TL-111; TL-112; Combination anti-angiogenic therapy (oral suspension, solid tumors), Tiltan Pharma
    Click to Show/Hide
External Link
TTD: D0T9OC
 Compound Name Antroquinonol Phase 2 [23]
Synonyms
Hocena; Fungal extract (cancer), Golden Biotechnology
    Click to Show/Hide
External Link
CID: 24875259
TTD: D0T3AW
DrugBank: DB12326
 Compound Name NPC-1C Phase 2 [23]
Synonyms
Ensituximab
    Click to Show/Hide
External Link
TTD: D0T2FC
 Compound Name Necuparanib Phase 2 [63]
External Link
TTD: D0S3CX
 Compound Name CCX872 Phase 2 [23]
External Link
TTD: D0Q3PB
 Compound Name GC4419 Phase 1/2 [23]
Synonyms
Avasopasem manganese; UNII-EY1WA413UL; EY1WA413UL; Avasopasem manganese [USAN]; SC-72325A; M-40419; 435327-40-5; Manganese, dichloro((4aS,13aS,17aS,21aS)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-7,11-nitrilo-7H-dibenzo(b,H)-5,13,18,21-tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22)-, (pb-7-11-2344'3')-
    Click to Show/Hide
External Link
CID: 71587734
TTD: D0PV9N
 Compound Name Istiratumab Phase 2 [42]
External Link
TTD: D0P4ZR
 Compound Name GI-4000 Phase 2 [64]
External Link
TTD: D0N4SF
 Compound Name OCV-101 Phase 2 [65]
Synonyms
OTS-11101
    Click to Show/Hide
External Link
TTD: D0LX8Z
 Compound Name RX-3117 Phase 2 [23]
Synonyms
Antimetabolite (cancer), Rexahn; Antimetabolite (cancer), Rexahn/ Teva
    Click to Show/Hide
External Link
CID: 11242315
TTD: D0L7WS
 Compound Name Ensitiximab Phase 2 [37]
External Link
TTD: D0KL4T
 Compound Name GI-4000 + gemcitabine Phase 2 [66]
External Link
TTD: D0KK9V
 Compound Name BC-819 Phase 2 [67]
External Link
TTD: D0K0KQ
 Compound Name IRT-102 Phase 2 [68]
External Link
CID: 42785
TTD: D0J5UK
 Compound Name LE-DT Phase 2 [69]
Synonyms
Liposomal docetaxel
    Click to Show/Hide
External Link
TTD: D0J2NX
 Compound Name TH-302 Phase 2 [23]
Synonyms
evofosfamide; 918633-87-1; TH 302; TH302; UNII-8A9RZ3HN8W; Evofosfamide(TH 302); n,n'-bis(2-bromoethyl)phosphorodiamidic acid (1-methyl-2-nitro-1h-imidazol-5-yl)methyl ester; 8A9RZ3HN8W; compound 3b; Evofosfamide;HAP-302; Phosphorodiamidic acid, N,N'-bis(2-bromoethyl)-, (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester; 2-bromo-N-[(2-bromoethylamino)-[(3-methyl-2-nitroimidazol-4-yl)methoxy]phosphoryl]ethanamine; Evofosfamide [USAN:INN]; Evofosfamide(TH-302); C9H16Br2N5O4P; CHEMBL260046; SCHEMBL2357174
    Click to Show/Hide
External Link
CID: 11984561
TTD: D0H1EA
DrugBank: DB06091
 Compound Name Demcizumab Phase 2 [37]
External Link
TTD: D0GJ7N
 Compound Name Anti-PSCA mab Phase 2 [70]
External Link
TTD: D0G7ZT
 Compound Name ALT-803 Phase 2 [42]
Synonyms
IL-15 agonist/ IL-15R alpha-Fc fusion complex (cancer), Altor BioScience
    Click to Show/Hide
External Link
TTD: D0FD7H
 Compound Name ARQ 761 Phase 2 [23]
External Link
TTD: D0DR0P
 Compound Name Reolysinpelareorep Phase 2 [23]
External Link
TTD: D0CW2N
 Compound Name PBI-05204 Phase 2 [23]
External Link
CID: 11541511
TTD: D0A4YK
DrugBank: DB12843
 Compound Name PCI-27483 Phase 2 [71]
External Link
CID: 135425273
TTD: D09TFL
DrugBank: DB13000
 Compound Name RX-0201 Phase 2 [37]
External Link
TTD: D07SYZ
 Compound Name CP-613 Phase 2 [72]
External Link
TTD: D07FXF
 Compound Name CART 19 Preclinical [73]
External Link
TTD: D06TKR
 Compound Name VT-122 Phase 1 [37]
External Link
TTD: D05VKS
 Compound Name PEGPH20 Phase 2 [74]
External Link
TTD: D05INV
 Compound Name Ficlatuzumab Phase 2 [23]
Synonyms
AV-299
    Click to Show/Hide
External Link
TTD: D03UBW
 Compound Name Tigatuzumab Phase 2 [75]
External Link
TTD: D03LTO
 Compound Name CRS-207 Phase 2 [76]
External Link
TTD: D02WSB
 Compound Name CAP1-6D Phase 2 [77]
Synonyms
Modified CEA peptide (pancreatic cancer), University of Chicago
    Click to Show/Hide
External Link
CID: 396060
TTD: D02UKX
 Compound Name SGT-53 Phase 2 [23]
Synonyms
P53 gene stimulator (solid tumor), Synergene Therapeutics
    Click to Show/Hide
External Link
TTD: D02EOH
 Compound Name Tarextumab Phase 2 [78]
External Link
TTD: D01QLP
 Compound Name BVD-523 Phase 2 [23]
External Link
CID: 11719003
TTD: D01IED
DrugBank: DB13930
 Compound Name Ocaperidone Phase 2 [42]
Synonyms
Ocaperidona; 129029-23-8; UNII-26HUS7139V; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 26HUS7139V; Ocaperidonum; Ocaperidonum [INN-Latin]; Ocaperidona [INN-Spanish]; 4H-Pyrido[1,2-a]pyrimidin-4-one,3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-; Ocaperidone (USAN); Ocaperidone [USAN:INN:BAN]; 3-[2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[440]deca-2,4,8,10-tetraen-7-one; FG-3019
    Click to Show/Hide
External Link
CID: 71351
TTD: D01FQR
DrugBank: DB06229
 Compound Name Encapsulated live cells converting ifosfamide Phase 2 [23]
External Link
TTD: D01DLT
 Compound Name LY2603618 Phase 2 [79]
Synonyms
Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618 IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea
    Click to Show/Hide
External Link
CID: 11955855
TTD: D00NZL
DrugBank: DB11662
 Compound Name Salirasib Discontinued in Phase 1/2 [80]
Synonyms
162520-00-5; Farnesylthiosalicylic acid; S-Farnesylthiosalicylic acid; UNII-MZH0OM550M; MZH0OM550M; CHEMBL23293; AK186909; Farnesyl Thiosalicylic Acid; 2-[[(2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrien-1-yl]thio]benzoic Acid; 2-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylbenzoic acid; 2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienylthio)benzoic acid; 2-(((2E,6E)-3,7,11-Trimethyl-2,6,10-dodecatrienyl)sulfanyl)benzoic acid; Benzoic acid, 2-(((2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrienyl)thio)-; FTS; Farnesylthiosalicyclic acid; FTS, Thyreos; Ras antagonists, Thyreos; S-trans; Th-101; Trans-farnesylthiosalicylicacid; FTS (oral, cancer), Concordia; Farnesylthiosalicyclic acid (oral, cancer), Concordia; Ras-inhibitors (cancer), Concordia; FTS (oral, cancer), Concordia/Ono; KD032
    Click to Show/Hide
External Link
CID: 5469318
TTD: D00KTV
DrugBank: DB12681
 Compound Name MM-141 Phase 2 [23]
External Link
TTD: D00BUO
 Compound Name GB1275 Phase 1/2 [81]
External Link
TTD: DZ5K6F
 Compound Name ABTL0812 Phase 1/2 [82]
Synonyms
(9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; (9Z,12Z)-2-hydroxyoctadecadienoic acid; (alpha)-Hydroxylinoleic acid; .ALPHA.-HYDROXYLINOLEIC ACID; 0DE74TJ7EZ; 2-hydroxy-9Z,12Z-Octadecadienoic acid; 2-hydroxylinoleic acid; 57818-44-7; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; ABTL0812; ABTL-0812; a-Hydroxylinoleic acid; AKOS040740632; alpha-Hydroxylinoleic acid; CHEBI:136927; CS-7178; DTXSID301258077; hydroxylinoleic acid; HY-U00141; LMFA02000290; MS-24253; s9611; SCHEMBL320069; UNII-0DE74TJ7EZ
    Click to Show/Hide
External Link
CID: 21158511
TTD: DMBQ10
 Compound Name GP-2250 Phase 1/2 [83]
External Link
TTD: DARV32
 Compound Name Delolimogene mupadenorepvec Phase 1/2 [84]
Synonyms
LOAd703
    Click to Show/Hide
External Link
TTD: D5V7XP
 Compound Name GSK3145095 Phase 1/2 [85]
Synonyms
1622849-43-7; CHEMBL4452233; (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide; UNII-B4D3WPS7JY; B4D3WPS7JY; SCHEMBL17312826; BCP31015; EX-A3069; BDBM50502339; s8845; GSK-3145095; HY-111946; CS-0094287; GSK 3145095; FC1=CC2=C(NC(=O)[C@H](CC2)NC(=O)C2=NN=C(CC3=CC=CC=C3)N2)C(F)=C1; (S)-5-Benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1hbenzo(b)azepin-3-yl)-1H-1,2,4-triazole-3-carboxamide (7,7-dimethyl-2- oxobicyclo(2.2.1)heptan-1-yl)
    Click to Show/Hide
External Link
CID: 118557502
TTD: D0Z7BX
 Compound Name Encapsulated cell therapy Phase 1/2 [86]
External Link
TTD: D0XY8C
 Compound Name ETBX-011 cancer vaccine Phase 1/2 [64]
External Link
TTD: D0U1WU
 Compound Name BPX-601 Phase 1/2 [87]
External Link
TTD: D0TY6U
 Compound Name NANT Phase 1/2 [23]
External Link
TTD: D0T4GG
 Compound Name BrevaRex Phase 1/2 [88]
Synonyms
BrevaRex MAb; monoclonal antibody
    Click to Show/Hide
External Link
TTD: D0M5JC
 Compound Name DCVax-Pancreas Phase 1/2 [89]
Synonyms
Dendritic cell-based immunotherapy (pancreatic cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D0L7LT
 Compound Name PEGylated hyaluronidase (human recombinant) Phase 1/2 [90]
Synonyms
PEGylated hyaluronidase; PEGylated hyaluronidase (human recombinant) (intravenous, stroke/cancer), Halozyme
    Click to Show/Hide
External Link
TTD: D0L5IA
 Compound Name CAR-T cells targeting mesothelin Phase 1/2 [91]
External Link
TTD: D0KC2S
 Compound Name MALP-2S Phase 1/2 [92]
External Link
TTD: D0K3SM
 Compound Name Anti-Mesothelin CAR-T cells Phase 1/2 [93]
External Link
TTD: D0BE6M
 Compound Name Anti-MUC1 CAR T Cells Phase 1/2 [94]
External Link
TTD: D08WII
 Compound Name Anti-HER2 CAR-T Phase 1/2 [95]
External Link
TTD: D08QZH
 Compound Name CAR-T Cells targeting EpCAM Phase 1/2 [96]
External Link
TTD: D08QYW
 Compound Name Anti-MUC1 AR20.5 Phase 1/2 [42]
External Link
TTD: D07YGQ
 Compound Name AR20.5 Phase 1/2 [23]
External Link
TTD: D07PCZ
 Compound Name G0-203-2c Phase 1/2 [97]
External Link
TTD: D04WHM
 Compound Name LOAd703 Phase 1/2 [23]
External Link
TTD: D03ZIP
 Compound Name Anti-mesothelin CAR transduced PBL Phase 1/2 [98]
External Link
TTD: D00YXG
 Compound Name M9241 Phase 1 [99]
Synonyms
NHS-IL12
    Click to Show/Hide
External Link
TTD: DO8W9E
 Compound Name NBF-006 Phase 1 [100]
External Link
TTD: D8UZ5R
 Compound Name AB680 Phase 1 [101]
Synonyms
AB-680; UNII-J6K8WSV73A; J6K8WSV73A; CHEMBL4471306; 2105904-82-1; (((((2R,3S,4R,5R)-5-(6-chloro-4-(((S)-1-(2-fluorophenyl)ethyl)amino)-1H-pyrazolo[3,4-b]pyridin-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)methyl)phosphonic acid; [[(2~{R},3~{S},4~{R},5~{R})-5-[6-chloranyl-4-[[(1~{S})-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl]methylphosphonic acid; SCHEMBL19100484; GTPL10707; BDBM50527134; HY-125286; CS-0090231; [[(2R,3S,4R,5R)-5-[6-chloro-4-[[(1S)-1-(2-fluorophenyl)ethyl]amino]pyrazolo[3,4-b]pyridin-1-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]methylphosphonic acid; QDH
    Click to Show/Hide
External Link
CID: 130205852
TTD: D7CE6N
 Compound Name STAT400 Phase 1 [102]
External Link
TTD: D75WVO
 Compound Name CEND-1 Phase 1 [103]
Synonyms
iRGD; UNII-Z8MXU5GH4Q; Z8MXU5GH4Q; iRGD-peptide; 1392278-76-0; Internalized-arginylglycylaspartic acid cyclic peptide; Q48988348; L-Cysteine, L-cysteinyl-L-arginylglycyl-L-alpha-aspartyl-L-lysylglycyl-L-prolyl-L-alpha-aspartyl-, cyclic (1->9)-disulfide
    Click to Show/Hide
External Link
CID: 134611625
TTD: D5WU7B
 Compound Name CAR-T Cells targeting EGFRvIII Phase 1 [104]
External Link
TTD: D0ZQ6N
 Compound Name HuCART-meso cells Phase 1 [105]
External Link
TTD: D0ZF9J
 Compound Name OCV-105 Phase 1 [106]
Synonyms
Cancer vaccine (pancreas), Otsuka/OncoTherapy
    Click to Show/Hide
External Link
TTD: D0X9YB
 Compound Name SBP-101 Phase 1 [37]
Synonyms
diethyl dihydroxyhomospermine
    Click to Show/Hide
External Link
TTD: D0VE9F
 Compound Name RG7882 Phase 1 [42]
External Link
TTD: D0V7QW
 Compound Name CART-meso-19 T cells Phase 1 [107]
External Link
TTD: D0V5DD
 Compound Name MOv19-BBz CAR T cells Phase 1 [108]
External Link
TTD: D0T7CR
 Compound Name Anti-MUC1 AR20.5 mab Phase 1 [109]
External Link
TTD: D0S3AE
 Compound Name Anti-CEA-CAR T Phase 1 [110]
External Link
TTD: D0S1QN
 Compound Name MVT-5873 Phase 1 [42]
External Link
TTD: D0Q5QV
 Compound Name CART-meso cells Phase 1 [111]
External Link
TTD: D0P2GA
 Compound Name CAR-20/19-T Cells Phase 1 [112]
External Link
TTD: D0NU9L
 Compound Name CARTmeso/19 Phase 1 [113]
External Link
TTD: D0MD8S
 Compound Name CAR-T Cells targeting Mesothelin Phase 1 [104]
External Link
TTD: D0L7OJ
 Compound Name CAR-T Cells targeting CEA Phase 1 [104]
External Link
TTD: D0L6HU
 Compound Name HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine Phase 1 [114]
Synonyms
HLA-A*2402-restricted KIF20A and VEGFR-1 epitope peptide vaccine (pancreatic cancer, subcutaneous)
    Click to Show/Hide
External Link
TTD: D0K6UQ
 Compound Name Anti-hCD70 CAR transduced PBL Phase 1 [115]
External Link
TTD: D0JO9M
 Compound Name MORAb-066 Phase 1 [116]
Synonyms
Anti-tissue factor monoclonal antibody (pancreatic tumor), Morphotek
    Click to Show/Hide
External Link
TTD: D0H8PX
 Compound Name Anti-MUC1 mab Phase 1 [117]
External Link
TTD: D0H2CF
 Compound Name Anti-meso-CAR vector transduced T cells Phase 1 [118]
External Link
TTD: D0G4GY
 Compound Name CRS-207 + GVAX Phase 2 [37]
External Link
TTD: D0EY1Y
 Compound Name Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 Phase 1 [119]
External Link
TTD: D0EB0Y
 Compound Name Meso-CART Phase 1 [120]
External Link
TTD: D0D2LE
 Compound Name ASG-5ME Phase 1 [121]
External Link
TTD: D0BC6M
 Compound Name Anti-CD133-CAR vector-transduced T cells Phase 1 [122]
External Link
TTD: D09HRH
 Compound Name IRX4204 Phase 1 [23]
Synonyms
220619-73-8; CHEMBL75133; UNII-877M97Z38Y; VTP-194204; 877M97Z38Y; KB-145960; SCHEMBL3437269; MolPort-042-665-869; ZINC1550770; IRX-4204; 3-Methyl-5-[2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid; BDBM50101445; DB11806; VTP 194204; (+)-VTP-194204; AGN 4204; (2E,4E)-3-Methyl-5-[(1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-cyclopropyl]-penta-2,4-dienoic acid
    Click to Show/Hide
External Link
CID: 9863341
TTD: D09DJC
DrugBank: DB11806
 Compound Name AbGn-107 Phase 1 [23]
External Link
TTD: D08GZE
 Compound Name LMB-100 Phase 1/2 [23]
External Link
TTD: D07RDQ
 Compound Name PLX7486 Phase 1 [123]
External Link
TTD: D07PSL
 Compound Name CAR-T Cells targeting HER2 Phase 1 [104]
External Link
TTD: D06XWD
 Compound Name CAR-T Cells targeting MUCI Phase 1 [104]
External Link
TTD: D06URX
 Compound Name SEL-403 Phase 1 [23]
External Link
TTD: D03ZLN
 Compound Name CAR-T Cells targeting PSCA Phase 1 [104]
External Link
TTD: D02MYI
 Compound Name Anti-CEA CAR-T cells Phase 1 [124]
External Link
TTD: D00KDQ
 Compound Name MVT-1075 Phase 1 [23]
External Link
TTD: D00IFQ
 Compound Name CAR-CLD18 T cell Clinical trial [125]
External Link
TTD: D06CWZ
 Compound Name CART-meso cells Clinical trial [126]
External Link
TTD: D04WZL
 Compound Name PMID28460551-Compound-1 Patented [127]
External Link
CID: 25190990
TTD: D0IH3I
DrugBank: DB14866
 Compound Name Tanomastat Discontinued in Phase 3 [128]
Synonyms
Tanomastat (USAN/INN); (2S)-4-[4-(4-chlorophenyl)phenyl]-4-oxo-2-(phenylsulfanylmethyl)butanoic acid
    Click to Show/Hide
External Link
CID: 6918336
TTD: D0Q1CD
DrugBank: DB06276
 Compound Name Larotaxel Discontinued in Phase 3 [129]
Synonyms
Benzenepropanoic acid; PNU 100940; XRP 9881; XRP9881
    Click to Show/Hide
External Link
CID: 6918260
TTD: D0J0RV
DrugBank: DB12984
 Compound Name Apricoxib Discontinued in Phase 2 [130]
Synonyms
TG01
    Click to Show/Hide
External Link
CID: 9820073
TTD: D0S7IZ
DrugBank: DB12378
 Compound Name Lintitript Discontinued in Phase 2 [131]
Synonyms
SR 27897; SR 27897B; SR27897; SR-27897; SR-27897B; 1-((2-(4-(2-Chlorophenyl)thiazol-2-yl)aminocarbonyl)indolyl)acetic acid; 2-((4-(o-Chlorophenyl)-2-thiazolyl)carbamoyl)indole-1-acetic acid; 2-[2-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]carbamoyl]indol-1-yl]acetic acid
    Click to Show/Hide
External Link
CID: 122077
TTD: D01ZXW
DrugBank: DB04867
 Compound Name Merbarone Discontinued in Phase 2 [132]
Synonyms
NSC-336628
    Click to Show/Hide
External Link
CID: 4990817
TTD: D00VZF
 Compound Name LY293111 Discontinued in Phase 2 [133]
Synonyms
Etalocib; 161172-51-6; UNII-THY6RIW44R; LY 293111; THY6RIW44R; CHEMBL329123; LY-193111; 2-[3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]-2-propylphenoxy]benzoic acid; VML295; Etalocib [USAN:INN]; Etalocib (USAN); GTPL2948; SCHEMBL1649516; CTK8E7596; C33H33FO6; VML 295; DTXSID70167073; YFIZRWPXUYFCSN-UHFFFAOYSA-N; MolPort-009-019-411; ZINC3930629; AC1L4328; PDSP2_001221; BDBM50029450; PDSP1_001237; 1758AH; DB12850; RT-013626; D04074; L001468; J-009797; Benzoic acid, 2-(3-(3-((5-ethyl-4'-fluoro-2-hydroxy(1,1'-bipheny
    Click to Show/Hide
External Link
CID: 177941
TTD: D00GNK
DrugBank: DB12850
 Compound Name HMN-214 Discontinued in Phase 1 [134]
Synonyms
N-(4-methoxyphenyl)sulfonyl-N-[2-[(E)-2-(1-oxidopyridin-4-yl)ethenyl]phenyl]acetamide; (E)-4-(2-(2-(N-Acetyl-N-((p-methoxyphenyl)sulfonyl)amino)phenyl)ethenyl)pyridine 1-oxide
    Click to Show/Hide
External Link
CID: 9888590
TTD: D0R7ID
 Compound Name RG7600 Discontinued in Phase 1 [135]
External Link
TTD: D04TYP
 Compound Name IC261 Preclinical [136]
Synonyms
IC-261; IC 261
    Click to Show/Hide
External Link
CID: 5288600
TTD: D0UN8H
DrugBank: DB03083
 Compound Name ANAVEX 1007 Preclinical [137]
External Link
TTD: D0M6OW
 Compound Name IPH-4201 Terminated [138]
Synonyms
MAb-16D10; MAb-J28; FAPP-targeting mAb (pancreatic cancer), Innate Pharma; FAPP-targeting mAb (pancreatic cancer), Universite de la Mediterranee/ INSERM; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Innate Pharma; Feto-acinar pancreatic protein-targeting monoclonal antibodies (pancreatic cancer), Universite de la Mediterranee/ INSERM
    Click to Show/Hide
External Link
TTD: D0F6HW
 Compound Name MesoTarg Investigative [139]
External Link
TTD: D0W5KO
 Compound Name PAT-PM-1 Investigative [139]
Synonyms
PM-1; Human monoclonal antibody (pancreatic cancer), Patrys; Human MAb (pancreas cancer), OncoMab/ Acceptys; Human monoclonal antibody (pancreatic cancer), OncoMab/ Acceptys; PM-1 antibody, OncoMab/ Acceptys
    Click to Show/Hide
External Link
TTD: D0U9YV
 Compound Name OP-04 Investigative [139]
Synonyms
OP-04 program (prodrug, pancreatic cancer); OP-04 program (prodrug, pancreatic cancer), Onco-Pharmakon
    Click to Show/Hide
External Link
TTD: D0S0DY
 Compound Name VLI-27 Investigative [140]
Synonyms
AKT inhibitor (pancreatic cancer), NovaLead Pharma
    Click to Show/Hide
External Link
TTD: D0N7CY
 Compound Name GS-326 Investigative [139]
Synonyms
GS-326C
    Click to Show/Hide
External Link
CID: 3041004
TTD: D0LI3A
 Compound Name PX-12 Phase 2 [141]
External Link
CID: 219104
TTD: D0FT8G
DrugBank: DB05448
 Compound Name Prodigiosin Investigative [139]
External Link
CID: 135455579
TTD: D06YEE
 Compound Name Pbi-shPDX-1 LP Investigative [139]
External Link
TTD: D02FAI
 Compound Name Gastrin 17C diphtheria toxoid conjugate Investigative [139]
Synonyms
Gastrin 17C diphtheria toxoid conjugate (pancreatic cancer)
    Click to Show/Hide
External Link
TTD: D01PNR
 Compound Name HS-P1 Investigative [139]
Synonyms
HS-310; Endoplasmin modulator (pancreas tumor, HeatShock/fusion protein/antigen), Heat Biologics; Gp-96-Ig + unspecified tumor antigen secreting live cell vaccine (pancreas tumor, HeatShock), Heat Biologics
    Click to Show/Hide
External Link
CID: 71537
TTD: D00JKJ
References
Ref 1 m6A methylation regulates hypoxia-induced pancreatic cancer glycolytic metabolism through ALKBH5-HDAC4-HIF1alpha positive feedback loop. Oncogene. 2023 Jun;42(25):2047-2060. doi: 10.1038/s41388-023-02704-8. Epub 2023 May 6.
Ref 2 HDAC inhibitors: a 2013-2017 patent survey. Expert Opin Ther Pat. 2018 Apr 19:1-17. doi: 10.1080/13543776.2018.1459568. Online ahead of print.
Ref 3 Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8.
Ref 4 Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4.
Ref 5 Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010 Jun 24;53(12):4654-67.
Ref 6 Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9.
Ref 7 Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38.
Ref 8 Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33. doi: 10.1021/np400198r. Epub 2013 Oct 28.
Ref 9 Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25. doi: 10.1038/nchembio.1223. Epub 2013 Mar 24.
Ref 10 Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. doi: 10.1021/jm0303094.
Ref 11 N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. doi: 10.1016/j.bmcl.2009.02.029. Epub 2009 Feb 12.
Ref 12 Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differentiation, and inhibition of proliferation in Friend leukemic cells. J Med Chem. 2002 Jul 18;45(15):3296-309. doi: 10.1021/jm0208119.
Ref 13 Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates. J Med Chem. 2005 Feb 24;48(4):1019-32. doi: 10.1021/jm049207j.
Ref 14 Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. doi: 10.1021/jm051010j.
Ref 15 Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. doi: 10.1016/j.bmcl.2005.02.075.
Ref 16 Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. doi: 10.1021/jm0503749.
Ref 17 Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. doi: 10.1021/jm0303655.
Ref 18 Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. doi: 10.1016/j.bmcl.2003.09.007.
Ref 19 Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. doi: 10.1021/jm015568c.
Ref 20 New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. doi: 10.1016/j.bmcl.2008.02.007. Epub 2008 Feb 8.
Ref 21 Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. doi: 10.1016/j.bmcl.2004.02.062.
Ref 22 Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. doi: 10.1016/j.bmcl.2004.03.012.
Ref 23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 24 US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression.
Ref 25 Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10. doi: 10.1016/j.bmcl.2007.09.005. Epub 2007 Sep 7.
Ref 26 TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 27 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7316).
Ref 28 ClinicalTrials.gov (NCT02110147) Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria. U.S. National Institutes of Health.
Ref 29 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 30 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
Ref 31 ClinicalTrials.gov (NCT01970371) A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE). U.S. National Institutes of Health.
Ref 32 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4920).
Ref 33 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688).
Ref 34 ClinicalTrials.gov (NCT03816163) A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 35 ClinicalTrials.gov (NCT01741194) AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext. U.S. National Institutes of Health.
Ref 36 Clinical pipeline report, company report or official report of Advantagene.
Ref 37 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 38 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8087).
Ref 39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018609)
Ref 40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004347)
Ref 41 ClinicalTrials.gov (NCT01579188) Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 42 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 43 Clinical pipeline report, company report or official report of Fibrogen.
Ref 44 ClinicalTrials.gov (NCT01523808) Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer. U.S. National Institutes of Health.
Ref 45 ClinicalTrials.gov (NCT01072981) Immunotherapy Study for Surgically Resected Pancreatic Cancer. U.S. National Institutes of Health.
Ref 46 ClinicalTrials.gov (NCT03504423) Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas. U.S. National Institutes of Health.
Ref 47 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.
Ref 48 ClinicalTrials.gov (NCT01494506) Study of MM-398 With or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 49 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5220).
Ref 50 ClinicalTrials.gov (NCT02923921) Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (Sequoia). U.S. National Institutes of Health.
Ref 51 ClinicalTrials.gov (NCT00337389) Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.. U.S. National Institutes of Health.
Ref 52 ClinicalTrials.gov (NCT01836432) Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. U.S. National Institutes of Health.
Ref 53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020300)
Ref 54 ClinicalTrials.gov (NCT03512756) A Randomized Phase 2/3 Multi-Center Study of SM-88 in Patients With Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 55 ClinicalTrials.gov (NCT04683939) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors. U.S.National Institutes of Health.
Ref 56 ClinicalTrials.gov (NCT03801915) Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers. U.S. National Institutes of Health.
Ref 57 ClinicalTrials.gov (NCT02650804) A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients. U.S.National Institutes of Health.
Ref 58 ClinicalTrials.gov (NCT04698915) Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 59 Clinical pipeline report, company report or official report of Cytocom
Ref 60 ClinicalTrials.gov (NCT02912949) A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy). U.S.National Institutes of Health.
Ref 61 ClinicalTrials.gov (NCT01233375) Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 62 ClinicalTrials.gov (NCT01659502) Investigator's Initiated Phase II Study for Pancreatic Cancer Patients. U.S. National Institutes of Health.
Ref 63 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022260)
Ref 64 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 65 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031248)
Ref 66 Clinical pipeline report, company report or official report of GlobeImmune.
Ref 67 ClinicalTrials.gov (NCT01413087) Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 68 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004141)
Ref 69 ClinicalTrials.gov (NCT01186731) Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 70 ClinicalTrials.gov (NCT01608711) A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002. U.S. National Institutes of Health.
Ref 71 ClinicalTrials.gov (NCT01020006) Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine. U.S. National Institutes of Health.
Ref 72 Clinical pipeline report, company report or official report of Cornerstone pharmaceuticals.
Ref 73 ClinicalTrials.gov (NCT02640209) Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)
Ref 74 ClinicalTrials.gov (NCT01839487) PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer. U.S. National Institutes of Health.
Ref 75 ClinicalTrials.gov (NCT01307891) Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer. U.S. National Institutes of Health.
Ref 76 ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health.
Ref 77 ClinicalTrials.gov (NCT00203892) Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 78 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8453).
Ref 79 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7960).
Ref 80 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026972)
Ref 81 ClinicalTrials.gov (NCT04060342) GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 82 ClinicalTrials.gov (NCT04431258) A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic. U.S.National Institutes of Health.
Ref 83 ClinicalTrials.gov (NCT03854110) Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine. U.S. National Institutes of Health.
Ref 84 ClinicalTrials.gov (NCT02705196) Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer. U.S.National Institutes of Health.
Ref 85 ClinicalTrials.gov (NCT03681951) First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 86 VC-01's Path to the Clinic. Viacyte. 2015.
Ref 87 ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
Ref 88 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010209)
Ref 89 Clinical pipeline report, company report or official report of Northwest BioTherapeutics.
Ref 90 ClinicalTrials.gov (NCT02346370) A Phase 1b/2, Study of Pegylated Recombinant Human Hyaluronidase Combined With Docetaxel Versus Docetaxel Alone in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC.. U.S. National Institutes of Health.
Ref 91 ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
Ref 92 Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase ... Br J Cancer. 2007 Sep 3;97(5):598-604.
Ref 93 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 94 ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor
Ref 95 ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Ref 96 ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 97 ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
Ref 98 ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Ref 99 ClinicalTrials.gov (NCT04327986) Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer. U.S. National Institutes of Health.
Ref 100 ClinicalTrials.gov (NCT03819387) A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer. U.S. National Institutes of Health.
Ref 101 ClinicalTrials.gov (NCT04104672) A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies. U.S. National Institutes of Health.
Ref 102 Clinical pipeline report, company report or official report of Statera Biopharma
Ref 103 ClinicalTrials.gov (NCT03517176) CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
Ref 104 ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.
Ref 105 ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer
Ref 106 Clinical pipeline report, company report or official report of Otsuka Pharmaceutical Co Ltd.
Ref 107 ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Ref 108 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 109 Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33.
Ref 110 ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer
Ref 111 ClinicalTrials.gov (NCT02159716) CART-meso in Mesothelin Expressing Cancers
Ref 112 ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells
Ref 113 ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer
Ref 114 Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer. Int J Oncol. 2014 Mar;44(3):662-8.
Ref 115 ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Ref 116 ClinicalTrials.gov (NCT01761240) Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC. U.S. National Institutes of Health.
Ref 117 Clinical pipeline report, company report or official report of Quest PharmaTech.
Ref 118 ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
Ref 119 ClinicalTrials.gov (NCT01897415) Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer
Ref 120 ClinicalTrials.gov (NCT02706782) A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma
Ref 121 2011 Pipeline of Seattle Genetics.
Ref 122 ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 123 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038879)
Ref 124 ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
Ref 125 ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
Ref 126 ClinicalTrials.gov (NCT03638193) Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer
Ref 127 Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015). Expert Opin Ther Pat. 2017 Jul;27(7):753-761. doi: 10.1080/13543776.2017.1325465. Epub 2017 May 5.
Ref 128 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6468).
Ref 129 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010227)
Ref 130 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026002)
Ref 131 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 890).
Ref 132 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000894)
Ref 133 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2948).
Ref 134 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010558)
Ref 135 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035599)
Ref 136 Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307.
Ref 137 2011 Pipeline of Anavex.
Ref 138 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017007)
Ref 139 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
Ref 140 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
Ref 141 A Randomized Phase II Study of PX-12, an Inhibitor of Thioredoxin in Patients With Advanced Cancer of the Pancreas Following Progression After a Gemcitabine-Containing Combination. Cancer Chemother Pharmacol. 2011 Mar;67(3):503-9.